Drug-drug interactions between COVID-19 therapeutics and psychotropic medications.
Expert Opin Drug Metab Toxicol
; 19(12): 925-936, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-38032183
ABSTRACT
INTRODUCTION:
The coronavirus (COVID-19) pandemic has led to as well as exacerbated mental health disorders, leading to increased use of psychotropic medications. Co-administration of COVID-19 and psychotropic medications may result in drug-drug interactions (DDIs), that may compromise both the safety and efficacy of both medications. AREAS COVERED This review provides an update of the current evidence on DDIs between COVID-19 and psychotropic medications. The interactions are categorized into pharmacokinetic, pharmacodynamic, and other relevant types. A thorough literature search was conducted using electronic databases to identify relevant studies, and extract data to highlight potential DDIs, clinical implications, and management strategies. EXPERT OPINION Understanding and managing potential DDIs between COVID-19 and psychotropic medications is paramount to ensuring safe and effective treatment of patients with COVID-19 and mental illness. Awareness of the diverse spectrum of DDIs, vigilant monitoring, and judicious dose modifications, while choosing pharmacotherapeutic options with low risk of interaction whenever possible, are necessary. Ongoing and future investigations should continue to review the dynamic landscape of COVID-19 therapeutic modalities and their interactions with psychotropic medications.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
COVID-19
/
Trastornos Mentales
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Drug Metab Toxicol
Asunto de la revista:
METABOLISMO
/
TOXICOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Italia